FDA

Regulatory calendar

Five FDA decisions to watch before the year ends

The next three months bring verdicts on a first-of-its-kind cancer immunotherapy, a twice-yearly cholesterol shot and a rare disease drug that has already been turned away once.

Oct. 5, 2026·FDA

FDA begins review of Nordlicht's multiple sclerosis pill

It is the first time the agency has accepted an application for a drug of this type in both relapsing and progressive forms of the disease.

Sept. 23, 2026·FDA